MiNK Therapeutics: In The Very Early Days Of A Big Hunt (NASDAQ:INKT)


T-Cells

Design Cells/iStock via Getty Images

Topline Summary

MiNK Therapeutics (NASDAQ:INKT) is a member of a small crowd of companies attempting to develop “off the shelf” allogeneic cell therapies for cancer and a few other indications. They’re hoping to leverage advances in



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *